Positive effects of ocrelizumab in patients with familial mediterranean fever and coexistent multiple sclerosis
Yazarlar (8)
Fırat Üniversitesi, Türkiye
Fırat Üniversitesi, Türkiye
Harran Üniversitesi, Türkiye
Prof. Dr. Dürdane AKSOY
Tokat Gaziosmanpaşa Üniversitesi, Türkiye
Türkiye
Türkiye
Erciyes Üniversitesi, Türkiye
Türkiye
| Makale Türü |
Özgün Makale
|
| Makale Alt Türü | SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale |
| Dergi Adı | Archives of Rheumatology |
| Dergi ISSN | 2148-5046 |
| Dergi Tarandığı Indeksler | SCI-Expanded |
| Dergi Grubu | Q3 |
| Makale Dili | İngilizce |
| Basım Tarihi | 06-2021 |
| Cilt No | 36 |
| Sayı | 2 |
| Sayfalar | 219 / 226 |
| DOI Numarası | 10.46497/ArchRheumatol.2021.8229 |
| Makale Linki | http://dx.doi.org/10.46497/archrheumatol.2021.8229 |
| Özet |
| Objectives: This study aims to evaluate the effects of ocrelizumab (OCZ) on familial Mediterranean fever (FMF) attacks in multiple sclerosis (MS) patients with FMF (MS+FMF patients).Patients and methods: This retrospective observational study included 11 patients (2 males, 9 females; mean age 46.6±9.2; range, 22 to 55 years) with MS+FMF hospitalized between January 2016 and July 2019. Demographic, clinical, and laboratory parameters and patient reported outcomes were analyzed in patients treated with OCZ for 18 months.Results: Combining OCZ with colchicine in MS+FMF patients significantly reduced the frequency of FMF attacks (p=0.003) and the frequency of joint attacks (p=0.002). Consistent with the clinical improvement, the maximum serum C-reactive protein levels were significantly decreased after combination therapy compared to before combination therapy (p=0.003). MS+FMF patients reported that FMF disease activity improved after OCZ therapy (Visual Analog Scale [VAS] 74±9.6 vs. VAS 46.5±8.1 mm, p=0.003).Conclusion: Ocrelizumab therapy led to a prominent decrease in the frequency of FMF attacks, alleviated functional impairment, and improved quality of life in MS+FMF patients. |
| Anahtar Kelimeler |
| Colchicine | resistant familial Mediterranean fever | familial Mediterranean fever | multiple sclerosis | ocrelizumab |
BM Sürdürülebilir Kalkınma Amaçları
| Atıf Sayıları | |
| WoS | 4 |
| Google Scholar | 4 |